Article Text

Download PDFPDF
Recommendations for HER2 testing in the UK
  1. I O Ellis1,
  2. M Dowsett2,
  3. J Bartlett3,
  4. R Walker4,
  5. T Cooke3,
  6. W Gullick5,
  7. B Gusterson6,
  8. E Mallon6,
  9. P Barrett Lee7
  1. 1Department of Histopathology, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
  2. 2Department of Biochemistry, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
  3. 3University Department of Surgery, Glasgow Royal Infirmary, Level II, Queen Elizabeth Building, Alexandra Parade, Glasgow G31 2ER, UK
  4. 4University of Leicester, Department of Pathology, School of Medicine, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UK
  5. 5Department of Biosciences, The University of Kent at Canterbury, Canterbury, Kent CT2 7NJ, UK
  6. 6Department of Pathology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
  7. 7Verlindre Hospital, Whitchurch, Cardiff DF4 7XL, UK
  1. Dr Ellis


Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin®), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.

  • HER2
  • breast cancer
  • Herceptin®

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.